MyVisionTest News Archive

Displaying news items tagged with Lucentis (More tags »)
SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last

Central retinal vein occlusion
Oct 22, 2009
Inhibition of VEGF in macular edema secondary to central retinal vein occlusion provides rapid and sustained visual acuity improvements through 6 months, according to a speaker at Retina Congress 2009. The data are from the phase 3 CRUISE trial on Lucentis (ranibizumab) vs. sham and will be presented to the U.S. Food and Drug Administration...

Full Article


Macular degeneration
Oct 21, 2009
A treat-and-extend therapy regimen may not completely resolve subretinal fluid in patients with newly diagnosed type 1 neovascularization, although patients in a retrospective study treated under the protocol maintained vision. In the study, 18 eyes of 16 patients were treated with three loading doses of Lucentis (ranibizumab) or Avastin (...

Full Article


Lucentis
Oct 16, 2009
A case report of worsening of ocular ischemic syndrome following Lucentis (ranibizumab) administration is reported It has been recently documented that Lucentis causes retinal arteriolar vasoconstiction, and this has the potential to induce or worsen retinal ischemia (oxygen deprivation). It has been suggested that anti-VEGF agents be used with...

Full Article


Canadian flag
Oct 15, 2009
A fundamental principle of the 1984 Canada Health Act is that Canadians should have access to medically necessary physician and hospital services according to need rather than ability to pay. However, national coverage for prescription medicines administered out of hospital was not included in the Act, although there have been policy calls for a...

Full Article


Lucentis
Sep 25, 2009
Lucentis (ranibizumab) had a beneficial effect on visual outcome, along with safe and well-tolerated results, in treating neovascular age-related macular degeneration (AMD), according to the SAILOR study. The SAILOR study was a phase IIIb follow-up study to the MARINA and ANCHOR studies to evaluate the long-term safety and efficacy of Lucentis...

Full Article


Lucentis
Sep 22, 2009
Intravitreal Lucentis (ranibizumab) may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration (AMD), according to a new research report. Methods and Results In this prospective study involving 11 patients with previously untreated neovascular AMD, all eyes had 3 monthly IVT injections of...

Full Article


Macular degeneration
Sep 21, 2009
A study from Korea finds that baseline visual acuity (VA) and choroidal neovascular membrane (CNV) size were predictive of vision outcome after Lucentis (ranibizumab) treatment for neovascular age-related macular degeneration (AMD). In the MARINA clinical trial of Lucentis therapy for AMD, the most important predictors of VA outcomes were, in...

Full Article


Intravitreal injection
Sep 19, 2009
The visual outcome of patients undergoing Lucentis (ranibizumab) therapy for exudative age-related macular degeneration (AMD) under an as-needed dosing schedule is related to the number of injections received but not to the resolution of fluid by optical coherence tomography (OCT), according to a new research study. The ANCHOR and MARINA...

Full Article


Lucentis
Sep 18, 2009
The results of Lucentis (ranibizumab) therapy for neovascular age-related macular degeneration (AMD) in a retinal specialty practice located in Paris, France are significantly worse than the results reported from the PrONTO study. The PrONTO study was designed to investigate the possibility of reducing the frequency of treatment with Lucentis...

Full Article


thermometer
Sep 17, 2009
A paper reports on two cases of fever following anti-VEGF injection. In the first case, a 76-year-old woman in good general health developed a fever (38.5-39.5° C) and chills 2-4 days following intravitreal injection of Avastin (bevacizumab) for age-related macular degeneration (AMD). The visual acuity was stable during the fever without...

Full Article


SELECT PAGE
First <<  1 2 3 4 5 6 7 8 9 10   >> Last
Most Popular
Less - past - More